JP2014034576A5 - - Google Patents

Download PDF

Info

Publication number
JP2014034576A5
JP2014034576A5 JP2013194611A JP2013194611A JP2014034576A5 JP 2014034576 A5 JP2014034576 A5 JP 2014034576A5 JP 2013194611 A JP2013194611 A JP 2013194611A JP 2013194611 A JP2013194611 A JP 2013194611A JP 2014034576 A5 JP2014034576 A5 JP 2014034576A5
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
medicament according
treatment
optionally substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013194611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014034576A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014034576A publication Critical patent/JP2014034576A/ja
Publication of JP2014034576A5 publication Critical patent/JP2014034576A5/ja
Pending legal-status Critical Current

Links

JP2013194611A 2007-04-10 2013-09-19 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 Pending JP2014034576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10
US60/922,899 2007-04-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010503045A Division JP2010523670A (ja) 2007-04-10 2008-04-09 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014059561A Division JP2014139217A (ja) 2007-04-10 2014-03-24 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Publications (2)

Publication Number Publication Date
JP2014034576A JP2014034576A (ja) 2014-02-24
JP2014034576A5 true JP2014034576A5 (OSRAM) 2014-07-17

Family

ID=39627802

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010503045A Pending JP2010523670A (ja) 2007-04-10 2008-04-09 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2013194611A Pending JP2014034576A (ja) 2007-04-10 2013-09-19 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2014059561A Pending JP2014139217A (ja) 2007-04-10 2014-03-24 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010503045A Pending JP2010523670A (ja) 2007-04-10 2008-04-09 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014059561A Pending JP2014139217A (ja) 2007-04-10 2014-03-24 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Country Status (31)

Country Link
US (1) US8513266B2 (OSRAM)
EP (1) EP2139484B9 (OSRAM)
JP (3) JP2010523670A (OSRAM)
KR (1) KR101626435B1 (OSRAM)
CN (2) CN101715345A (OSRAM)
AU (1) AU2008236562B2 (OSRAM)
BR (1) BRPI0810206A2 (OSRAM)
CA (1) CA2683641C (OSRAM)
CO (1) CO6251254A2 (OSRAM)
CR (1) CR11100A (OSRAM)
DK (1) DK2139484T3 (OSRAM)
DO (1) DOP2009000243A (OSRAM)
EA (1) EA020022B1 (OSRAM)
EC (1) ECSP099724A (OSRAM)
ES (1) ES2430614T3 (OSRAM)
HN (1) HN2009003002A (OSRAM)
HR (1) HRP20130688T1 (OSRAM)
IL (1) IL201284A (OSRAM)
MA (1) MA31358B1 (OSRAM)
ME (1) ME00936B (OSRAM)
MX (1) MX2009010930A (OSRAM)
MY (1) MY150697A (OSRAM)
NZ (1) NZ580110A (OSRAM)
PL (1) PL2139484T3 (OSRAM)
PT (1) PT2139484E (OSRAM)
RS (1) RS52939B (OSRAM)
SI (1) SI2139484T1 (OSRAM)
TN (1) TN2009000400A1 (OSRAM)
UA (1) UA100979C2 (OSRAM)
WO (1) WO2008124161A1 (OSRAM)
ZA (1) ZA200906764B (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
ES2430614T3 (es) 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
RS53020B (sr) * 2007-04-11 2014-04-30 Exelixis Inc. Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera
JP5654990B2 (ja) 2008-08-20 2015-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
EP2326626B1 (en) * 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
WO2012027536A1 (en) * 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012158960A2 (en) * 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
JP2014529298A (ja) * 2011-07-28 2014-11-06 ジェネンテック， インコーポレイテッド Ｐｉｋ３ｃａｈ１０４７ｒノックイン非ヒト動物乳癌モデル
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
AU2012332486A1 (en) 2011-11-01 2014-06-19 Arthur Decillis N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
CA2855666A1 (en) * 2011-11-11 2013-05-16 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US20150010545A1 (en) * 2011-12-27 2015-01-08 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
HK1211831A1 (zh) 2012-08-07 2016-06-03 Novartis Ag 包含B-RAF抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20180118719A (ko) 2016-03-04 2018-10-31 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN114394966B (zh) * 2016-08-15 2024-10-11 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
AU2019239404B2 (en) 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
BR112022011372A2 (pt) * 2019-12-10 2022-08-23 Univ Indiana Trustees Inibidores de interação de proteína a de replicação (rpa)-dna
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
JP2024542205A (ja) * 2021-11-18 2024-11-13 オンコノヴァ セラピューティクス， インコーポレイテッド がんを処置するための方法および組成物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
US7576074B2 (en) * 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
CA2555724A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
DE602005002562T2 (de) * 2004-05-04 2008-01-31 Warner-Lambert Company Llc Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
JP5216958B2 (ja) * 2005-07-06 2013-06-19 株式会社三和技術総合研究所 漏洩電流検出装置及び漏洩電流検出方法
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
JP5480503B2 (ja) 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
WO2007044729A2 (en) 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
HRP20110621T2 (hr) * 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
ES2430614T3 (es) 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
EP2142543B8 (en) 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
AU2008239596B2 (en) 2007-04-11 2013-08-15 Exelixis, Inc. Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
RS53020B (sr) 2007-04-11 2014-04-30 Exelixis Inc. Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor

Similar Documents

Publication Publication Date Title
JP2014034576A5 (OSRAM)
AR074575A1 (es) Compuesto de benzoimidazol-pirimidin-aminopiridina, forma cristalina iii relacionada, formulacion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un cancer
JP2019501204A5 (OSRAM)
JP2010523669A5 (OSRAM)
JP2014518544A5 (OSRAM)
TR201807411T4 (tr) DNA-PK inhibitörleri.
JP2018504418A5 (OSRAM)
HRP20131081T1 (hr) Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera
JP2010523670A5 (OSRAM)
JP2016503414A5 (OSRAM)
RU2013148732A (ru) Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
EA201690608A1 (ru) Способы лечения раковых заболеваний
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CO6251254A2 (es) Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer
RU2012139825A (ru) Антагонисты неурегулина и применение их в лечении злокачественного новообразования
RU2015143437A (ru) Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
JP2015512398A5 (OSRAM)
RU2018138627A (ru) Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
RU2013150102A (ru) Ингибиторы parp для лечения cipn
JP2013523843A5 (OSRAM)
AR080151A1 (es) Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP2013520431A5 (OSRAM)